These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28766916)

  • 1. Interleukin-18 (IL-18) is equally expressed in inflammatory breast cancer and noninflammatory locally advanced breast cancer: A possible association with chemotherapy response.
    Aguiar MAN; Wanderley CWS; Nobre LMS; Alencar MRM; Saldanha MDPS; Souza AM; Wong DVT; Barros PG; Almeida PRC; Lima-Júnior RCP; Ribeiro RA
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e138-e144. PubMed ID: 28766916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
    van Uden DJ; Bretveld R; Siesling S; de Wilt JH; Blanken-Peeters CF
    Breast Cancer Res Treat; 2017 Apr; 162(2):365-374. PubMed ID: 28138891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative study of inflammatory and non-inflammatory locally advanced breast cancer - the experience of a Moroccan hospital].
    Benbrahim Z; Berrada A; Amaadour L; Zahra El M'rabet F; Elfatemi H; Elfakir S; Mellas N; Arifi S
    Gynecol Obstet Fertil Senol; 2017 Nov; 45(11):604-608. PubMed ID: 29100820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study.
    Dawood S; Ueno NT; Valero V; Woodward WA; Buchholz TA; Hortobagyi GN; Gonzalez-Angulo AM; Cristofanilli M
    Cancer; 2011 May; 117(9):1819-26. PubMed ID: 21509759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
    Arias-Pulido H; Cimino-Mathews AM; Chaher N; Qualls CR; Joste N; Colpaert C; Marotti JD; Chamberlin MD; Foisey MG; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2021 Dec; 190(3):477-489. PubMed ID: 34542773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory
    Monneur A; Goncalves A; Gilabert M; Finetti P; Tarpin C; Zemmour C; Extra JM; Tallet A; Lambaudie E; Jacquemier J; Houvenaeghel G; Boher JM; Viens P; Bertucci F
    Oncotarget; 2017 Sep; 8(39):66019-66032. PubMed ID: 29029489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?
    Anderson WF; Chu KC; Chang S
    J Clin Oncol; 2003 Jun; 21(12):2254-9. PubMed ID: 12805323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer.
    Levine PH; Portera CC; Hoffman HJ; Yang SX; Takikita M; Duong QN; Hewitt SM; Swain SM
    Clin Breast Cancer; 2012 Aug; 12(4):232-9. PubMed ID: 22694825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
    Van Laere SJ; Van der Auwera I; Van den Eynden GG; Elst HJ; Weyler J; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3249-56. PubMed ID: 16740744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
    Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
    Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients.
    Chaher N; Arias-Pulido H; Terki N; Qualls C; Bouzid K; Verschraegen C; Wallace AM; Royce M
    Breast Cancer Res Treat; 2012 Jan; 131(2):437-44. PubMed ID: 21360074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages.
    Mohamed HT; El-Husseiny N; El-Ghonaimy EA; Ibrahim SA; Bazzi ZA; Cavallo-Medved D; Boffa MB; El-Shinawi M; Mohamed MM
    Curr Probl Cancer; 2018; 42(2):215-230. PubMed ID: 29459177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.
    Hance KW; Anderson WF; Devesa SS; Young HA; Levine PH
    J Natl Cancer Inst; 2005 Jul; 97(13):966-75. PubMed ID: 15998949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
    Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
    Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?
    Il'yasova D; Siamakpour-Reihani S; Akushevich I; Akushevich L; Spector N; Schildkraut J
    Breast Cancer Res Treat; 2011 Nov; 130(2):691-7. PubMed ID: 21850396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers.
    Kai M; Kogawa T; Liu DD; Fouad TM; Kai K; Niikura N; Hsu L; Willey JS; Theriault RL; Valero V; Ueno NT
    Clin Breast Cancer; 2015 Feb; 15(1):37-42. PubMed ID: 25258308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
    Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
    Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
    Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN
    Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory breast cancer: is it really a separate entity?
    Bastawisy A; Gaafar R; Eisa S; Amira G; Helal M
    Ecancermedicalscience; 2012; 6():250. PubMed ID: 22570674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.